Volpara Health is collaborating with Microsoft to accelerate research and development of software that uses mammograms to identify potential cardiovascular issues
- Heart disease is the leading cause of death for American women
- Breast artery calcifications* have been shown to be associated with cardiovascular disease outcomes1
- The intention of the collaboration is to expand the ability of breast cancer screening programs to perform cardiovascular assessments from routine mammograms
- Volpara Health, based in WellingtonNZ, is a leader in artificial intelligence for breast cancer detection and risk assessment
SEATTLE, August 4, 2022 /PRNewswire/ — Volpara Health Technologies (“Volpara”, “the Group” or “the Company”; ASX: VHT), a global leader in health technology software providing an integrated platform for personalized breast care, today announced a new research and development agreement with Microsoft to accelerate the creation of a solution that detects and quantifies mammary arterial calcifications (BAC).
This collaboration demonstrates a commitment to improving women’s health through science and innovation. The solution will build on Volpara’s approach to quantitative and objective breast density scoring using artificial intelligence (AI). Capitalize on Volpara’s recent BAC patent, the solution will create a tissue composition map that identifies and quantifies blood alcohol content from a mammogram, helping radiologists identify the need for action to prevent heart disease. The integration of Microsoft Azure Machine Learning, which is part of the Azure AI platform, will help improve Volpara’s BAC model and data processing.
This project is an expansion of the companies relationship over the past decade. Last year, Volpara’s innovative work in supporting healthcare providers was recognized with its SaaS (Software as a Service) award at the Microsoft New Zealand Partner Awards. Microsoft SaaS and cloud products have played a fundamental role in supporting Volpara’s development of the latest FDA-cleared version of its core AI algorithm. To date, the algorithm has been used to assess the breast composition of more than 14.5M women through Volpara’s analysis of more 67M mammography and tomosynthesis images. These images, representing one of the largest anonymized image datasets in the world, will be an essential resource for the BAC project.
The BAC product, as a cardiac decision support tool for radiologists, would mark Volpara’s entry into a new field of care, forming part of a US$146.4 billion2 cardiovascular disease market. With access to over 35% of the US breast cancer screening market, Volpara has the install base to facilitate product deployment and adoption, creating a new revenue stream. For women, the BAC product would add a new dimension to their regular breast screenings, providing important insight into their cardiovascular health. All significant results of the BAC could be delivered via the Volpara® Breast Health Platform™ directly to the healthcare provider or through Volpara’s partner network.
Recently, Volpara announced Teri Thomas as new CEOwith co-founder and former CEO Ralph Highman, PhD, in transition to Chief Science and Innovation Officer. In her new role, Highnam will spearhead the BAC initiative.
About the joint project, Highnam said, “The relationship of trust we have built with Microsoft over the years is important for Volpara’s future, especially our use of Azure for machine learning and software development. products. Our mission and vision for the future of healthcare aligns well with Microsoft’s. Although we are in the early stages of BAC product development, this collaboration will accelerate our efforts as we advance science together. »
“Early detection of heart disease can have life-saving implications. With early knowledge, patients can work with their doctor to stop or slow progression,” said Tom McGuinness, Corporate Vice President, Global Healthcare & Life Sciences, Microsoft. “The integration of Azure Machine Learning as a Service with Volpara’s solution enables providers to connect data and search for meaningful signals through predictive analytics. Using this technology, physicians can identify cardiac risk in patients who may not know they are at higher risk, they and their provider to take proactive steps for their health.”
*Breast artery calcifications are clusters and patterns of calcification that appear on the mammogram image and may indicate heart disease or high risk of disease.
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370385/#:~:text=The%20cardiovascular%20disease%20market%2C%20which%20includes%20hypertension%2C%20dyslipidaemia,1.8%25% 2C%20according to%20to%20business%20intelligence%20supplier%20GBI%20Research.
Authorization and additional information
This announcement has been authorized by the CEO of Volpara Health Technologies Limited.
About Volpara Health Technologies Limited (ASX: VHT)
Volpara Health Technologies is a world leader in the research and development of artificial intelligence for the early detection of breast cancer. Volpara’s software provides clinicians with information on breast density, compression, dose and quality, enabling them to provide their patients with personalized breast care and better risk assessment.
Founded in 2009 on research originally conducted in University of Oxford, Volpara has seen its technology and services used by clients and/or research projects in 40 countries. Volpara’s groundbreaking work is backed by 100 patents, over 200 peer-reviewed publications, the most rigorous safety certifications, and numerous trademarks and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016Volpara raised A$132 million. With offices at Seattle and BostonVolpara is based in WellingtonNew Zealand.
For more information, visit www.volparahealth.com.
About Microsoft Corp (Nasdaq “MSFT” @microsoft)
Microsoft is enabling digital transformation in the era of intelligent cloud and intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.
For more information, visit www.microsoft.com.
SOURCE Volpara Health